Tizanidine Tablet
Product Images NDC 35356-662

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 35356-662). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Tizanidinehcl2mg)

Image Description (Tizanidinehcl2mg)
Tizanidine 2 mg oral tablets packaging label distributed by Quality Care Products, LLC. The label states a package size of 180 tablets and includes details such as the GTIN, NDC 35356-0662-18, and the manufacturer Dr. Reddy's Laboratories Limited in India. The tablets are described as white, oval, with a bisecting score. Additional instructions warn to keep out of children's reach and store at 77 degrees Fahrenheit.*
FDA Label Image

Image Description (Fig1)

Image Description (Fig1)
A line graph comparing plasma Tizanidine concentration (ng/mL) over time (hours from dosing) for 2 mg Tizanidine tablets and capsules administered with and without food. The graph shows concentration peaks within the first few hours and a decline toward zero over 24 hours, distinguishing effects of dosage form and food intake.*
FDA Label Image

Image Description (Fig2)

Image Description (Fig2)
A line graph showing improvement in Ashworth Score over time (hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth Score, and the x-axis shows hours post-dose from 0 to 6. Error bars indicate variability for each time point.*
FDA Label Image

Image Description (Fig3)

Image Description (Fig3)
A line graph comparing improvement in Ashworth Score over time between tizanidine (mean dose 28.8 mg) and placebo groups. The x-axis shows study weeks (End of Titration at Week 3, End of Maintenance at Week 7, Endpoint with Last Observation Carried Forward). The y-axis measures improvement scores, with error bars for variability at each time point for both groups.*
FDA Label Image

Image Description (Structure)

Image Description (Structure)
Chemical structure of Tizanidine hydrochloride, showing the molecular framework with a chlorinated benzene ring fused to an imidazoline ring and a pyridine substituent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.